Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Sponsor: Memorial Sloan Kettering Cancer Center
Sponsor score: 60
ClinicalTrials ID:NCT00107289
This study evaluates the safety and efficacy of ^131I-MIBG in patients with resistant neuroblastoma, pheochromocytoma, or paraganglioma. Participants receive an initial dose of ^131I-MIBG, with potential for a second dose based on response and toxicity. Eligibility includes patients with recurrent, progressive, or refractory conditions. Follow-up occurs at 4-6 weeks and every 3 months for a year.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The purpose of this research study is to find how active and safe 131 I-MIBG is in patients with resistant neuroblastoma, malignant pheochromocytoma and malignant paraganglioma.
Eligibility Criteria
Exclusion Criteria
- Severe major organ toxicity. Specifically, renal, cardiac, hepatic, pulmonary, gastrointestinal and neurologic toxicity should all be grade 2 or less. A grade 3 hearing deficit is acceptable.
- Active serious infections not controlled by antibiotics.
- Pregnant women are excluded for fear of danger to the fetus. Therefore negative pregnancy test is required for all women of child-bearing age, and appropriate contraception is used during the study period.
- Inability or unwillingness to comply with radiation safety procedures or protocol requirements.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 10065 | New York | New York |
Get This Program In Your Inbox
You can sign up and apply your patients for this program.